It's is the testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics that excites me about this company.
Also The CEO Tony Frudakis was a lead scientist for Corixa
Tony Frudakis, PhD, Founder, Chief Scientific Officer Dr. Frudakis founded GAFF biologic, the predecessor in interest to DNAPrint, in 1998. He served as its President and Chief Executive Officer. Prior to founding GAFF biologic, Dr. Frudakis was a research scientist for Corixa Corporation for four years. While at Corixa he developed several new techniques for RNA fingerprinting, managed and executed high-throughput gene discovery programs for various cancers and was instrumental in the company's early success in attracting research and development partners. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, Magna cum laude graduate of the University of California Irvine where he received a BS degree in Biological Sciences. Dr. Frudakis also earned a doctorate degree in molecular and cell biology from the University of California Berkeley.
This is why I bought the stock 1) CEO (Dr. Tony Frudakis) Lead scientist for Corixa starts his own company a few months ago
2) Company is formed by a reverse merger of a pinksheet company
3) DNAP has already completed the accounting to get off the pinksheets and should be listed on the OTCBB soon.
4) Dr. Frudakis was responsible for a patent that sold for $54,000,000 to Smith Kline Beecham while he was at Corixa.
5) Corixa's stock has gone from 14 Cents a few years ago to 50 Dollars today.
6) According to the Barron's article (9/25/00 pg 52), Dnaprint is in the late stages of forming strategic alliances with major companies.
As you can see, this is another company taking its time to get to fruition. I'll TA this in a while to see if I should buy more in the future.
News 
Market Data 
Discover 
AI
